| Cite this article: |
| CAO Shuang,JIA Wenwen,HU Jia,TIAN Wei,LIU Mei,ZHU Jie,CHENG Nian.Effect of invigorating spleen and nourishing stomach on the level of tumor markers, immune function and long-term curative effect in elderly patients with advanced gastric cancer[J].Journal Of Pharmaceutical Research,2024,43(2):189-193[Click to copy] |
|
| 摘要: |
| 目的 探究健脾养胃法对老年胃癌晚期患者肿瘤标志物水平、免疫功能及长期疗效影响。方法收集我院2019年6月—2022年6月肿瘤科收治的晚期胃癌患者95例,随机分为对照组(47例)与试验组(48例)。对照组予以FOLFOX4方案进行化疗,试验组在对照组的基础上予以健脾养胃法。两组均治疗9周,治疗结束后比较2组中医症状积分、血清肿瘤标志物、免疫功能指标、治疗期间胃肠道反应、远期生存率。结果 治疗后与对照组相比,试验组临床有效率较高(P<0.05)。治疗后与治疗前相比2组脘腹痞闷、胸胁胀痛、纳差、便溏及神疲乏力等中医症状积分降低;与对照组相比,试验组所有中医症状积分均较低(P<0.05)。治疗后与治疗前相比2组CEA、CA12-5、CA19-9及CA72-4降低;与对照组相比,试验组CEA、CA12-5、CA19-9及CA72-4较低(P<0.05)。治疗后与治疗前相比2组CD4+/CD8+、C3+升高,IgG、IgM降低(P<0.05);与对照组相比,试验组CD4+/CD8+、C3+较高,IgG、IgM较低(P<0.05)。2组6个月及1年生存率相比无统计学意义(P>0.05);试验组3年内生存率高于对照组(P<0.05)。结论 健脾养胃法应用于老年胃癌晚期胃癌患者的治疗中近远期治疗效果显著,能提高免疫功能,下调肿瘤标志物水平,适宜临床应用。 |
| 关键词: 健脾养胃法 老年胃癌晚期 肿瘤标志物 免疫功能 长期疗效 |
| DOI:10.13506/j.cnki.jpr.2024.02.015 |
| 基金项目:河北省中医药管理局科研计划项目(No.2019018) |
|
|
|
| Effect of invigorating spleen and nourishing stomach on the level of tumor markers, immune function and long-term curative effect in elderly patients with advanced gastric cancer |
| CAO Shuang1,JIA Wenwen2,HU Jia3,TIAN Wei1,LIU Mei1,ZHU Jie4,CHENG Nian1 |
| (1.Department of Laboratory, Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang 050000,China;2.The Second Department of Spleen and Stomach, Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang 050000,China;3.Department of Laboratory, The Eighth Hospital of Shijiazhuang, Shijiazhuang 050081, China;4.Department of Clinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000,China) |
| Abstract: |
| Objective To explore the effects of invigorating the spleen and nourishing the stomach on the level of tumor markers, immune function and long-term efficacy in elderly patients with advanced gastric cancer. Methods 95 patients with advanced gastric cancer admitted to the gastroenterology department of our hospital from June 2019 to June 2022 were collected and randomly divided into control group (47 cases) and experimental group (48 cases). The control group was given FOLFOX4 regimen for chemotherapy, and the experimental group was given spleen-strengthening and stomach-nourishing method on the basis of the control group. Both groups were treated for 9 weeks. After treatment, TCM symptom scores, serum tumor markers, immune function indexes, gastrointestinal reactions and myelosuppression during treatment, and long-term survival rates were compared between the two groups.Results After treatment, the clinical effective rate of experimental group was higher than that of control group (P<0.05). After treatment, the scores of traditional Chinese medicine symptoms such as abdominal tightness, distention pain, poor appetite, loose stool and anesthesia in the 2 groups were reduced compared with before treatment. Compared with the control group, the scores of all TCM symptoms in experimental groups were lower (P<0.05). After treatment, CEA, CA12-5, CA19-9 and CA72-4 were decreased compared with before treatment. Compared with the control group,CEA,CA12-5,CA19-9 and CA72-4 in experimental groups were lower (P<0.05). After treatment, CD4+/CD8+ and C3+ increased, while IgG and IgM decreased in 2 groups compared with before treatment (P<0.05). Compared with the control group, CD4+/CD8+ and C3+ in experimental groups were higher, while IgG and IgM were lower (P<0.05). There was no significant difference in 6-month and 1-year survival rates between the two groups (P>0.05). The 3-year survival rate of experimental group was higher than that of control group (P<0.05).Conclusion Invigorating spleen and nourishing stomach has significant effect in the treatment of elderly patients with advanced gastric cancer, which can improve immune function and downregulate the level of tumor markers, and is suitable for clinical application. |
| Key words: Invigorating spleen and nourishing stomach Elderly patients with advanced gastric cancer Tumor marker Immune function Long-term efficacy |